TABLE 4.
Therapeutic outcomes of adalimumab therapy expressed per person ‘at risk’.
| 3 months |
6 months |
Overall |
|||||
|---|---|---|---|---|---|---|---|
| Outcome (persons) | Characteristic required to be ‘at risk’ |
Events/ At risk |
Percent with event, 95% CI |
Events/ At risk |
Percent with event, 95% CI |
Events/ person- year |
Incidence rate (95% CI) |
| Concomitant therapy | |||||||
| Discontinuation of topical steroid |
On topical steroid at baseline |
2/12 | 0.17 (0.05–0.45) | 1/12 | 0.08 (0.01–0.35) | 6/15.4 | 0.39 (0.18–0.85) |
| Reduction of prednisone to ≤10 mg/day |
>10 mg at baseline | 1/4 | 0.25 (0.05–0.70) | 2/4 | 0.50 (0.25–0.85) | 3/1.48 | 2.04 (0.42–5.96) |
| Discontinuation of other IMT |
On IMT at baseline | 5/20 | 0.25 (0.11–0.47) | 4/19 | 0.21 (0.09–0.43) | 8/19.3 | 0.41 (0.19–0.89) |
| Addition of other IMT | All patients | 1/22 | 0.05 (0.01–0.22) | 5/21 | 0.24 (0.11–0.45) | 5/27.7 | 0.18 (0.07–0.47) |
| Discontinuation | |||||||
| Discontinuation of adalimumab |
All patients | 4/22 | 0.18 (0.07–0.39) | 8/21 | 0.38 (0.21–0.59) | 12/24.4 | 0.49 (0.27–0.88) |
The unit of analysis is per person.
IMT, immunomodulatory therapy.